Fidelity reports 15% stake in Nektar Therapeutics

FMR LLC reports beneficial ownership of 4,303,188.37 shares of Nektar Therapeutics common stock, representing 15.0% of the class as of 03/31/2026.

Rhea-AI Filing Summary

FMR LLC reports beneficial ownership of 4,303,188.37 shares of Nektar Therapeutics common stock, representing 15.0% of the class as of 03/31/2026. The filing lists related interests held by Fidelity Growth Company Fund (5.6%, 1,608,001 shares) and Fidelity Growth Company Commingled Pool (6.5%, 1,861,842 shares) as of 03/31/2026. The schedule is filed under an amendment and is signed by an authorized representative pursuant to a Power of Attorney.

Insights

Institutional Ownership Analyst

FMR LLC holds a sizable passive stake in Nektar: 4,303,188.37 shares (15.0%).

FMR LLC’s Schedule 13G/A lists 15.0% beneficial ownership as of 03/31/2026. Two Fidelity-managed pools are identified with holdings above 5%: Fidelity Growth Company Fund (1,608,001 shares, 5.6%) and Fidelity Growth Company Commingled Pool (1,861,842 shares, 6.5%.

Because this is a 13G/A amendment, the filing characterizes the position as large but typically passive; subsequent trading activity will determine any change in influence. Cash‑flow treatment and voting arrangements beyond the stated sole dispositive power are not detailed in the excerpt.

Key Figures

FMR LLC beneficial ownership: 4,303,188.37 shares Percent of class: 15.0% Fidelity Growth Company Fund: 1,608,001 shares +2 more

5 metrics

FMR LLC beneficial ownership 4,303,188.37 shares Amount beneficially owned as of 03/31/2026

Percent of class 15.0% Percent of common stock as of 03/31/2026

Fidelity Growth Company Fund 1,608,001 shares Amount held (5.6%) as of 03/31/2026

Fidelity Growth Company Commingled Pool 1,861,842 shares Amount held (6.5%) as of 03/31/2026

Filing type Schedule 13G/A Amendment reporting beneficial ownership

Key Terms

Schedule 13G/A, Beneficially owned, Sole Dispositive Power, Power of Attorney

4 terms

Schedule 13G/A regulatory

"Amendment No. 1 ) NEKTAR THERAPEUTICS COMMON STOCK"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 4303188.37"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Dispositive Power regulatory

"7 | Sole Dispositive Power 4,303,188.37"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Power of Attorney legal

"Duly authorized under Power of Attorney effective as of April 13, 2026"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in Nektar Therapeutics (NKTR)?

FMR LLC reports beneficial ownership of 4,303,188.37 shares, equal to 15.0% of common stock as of 03/31/2026. This is the position reported on the Schedule 13G/A amendment.

Which Fidelity funds hold more than 5% of NKTR?

Two Fidelity vehicles are cited: Fidelity Growth Company Fund with 1,608,001 shares (5.6%), and Fidelity Growth Company Commingled Pool with 1,861,842 shares (6.5%), both as of 03/31/2026.

Does the filing indicate active control over Nektar by FMR LLC?

The filing reports sole dispositive power for 4,303,188.37 shares but does not describe active control measures. It is presented as an ownership disclosure on a Schedule 13G/A amendment.

What date is used for the ownership percentages in the filing?

All ownership figures in the excerpt are anchored to 03/31/2026, which is the reference date for the reported share counts and the resulting percentage figures.

Who signed the Schedule 13G/A amendment for FMR LLC?

The amendment is signed by Richard Bourgelas as a duly authorized representative, under a Power of Attorney effective 04/13/2026, with signatures dated 05/05/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 11:30 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

NEKTAR THERAPEUTICS

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

640268306

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 640268306

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,298,602.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,303,188.37
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,303,188.37

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 640268306

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,303,188.37
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,303,188.37

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NEKTAR THERAPEUTICS
(b)	Address of issuer's principal executive offices: 455 MISSION BAY BOULEVARD SOUTH,SAN FRANCISCO,CA,US,94158
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 640268306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4303188.37
(b)	Percent of class: 15.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 4303188.37
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of NEKTAR THERAPEUTICS. The interest of Fidelity Growth Company Fund, in the COMMON STOCK of NEKTAR THERAPEUTICS, amounted to 1608001.00 shares or 5.6% of the total outstanding COMMON STOCK at 03/31/2026. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of NEKTAR THERAPEUTICS, amounted to 1861842.00 shares or 6.5% of the total outstanding COMMON STOCK at 03/31/2026.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	05/05/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	05/05/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.